NCT05705492View on ClinicalTrials.gov

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

July 17, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
Advanced Malignant Solid NeoplasmAdvanced Biliary Tract CarcinomaAdvanced Esophageal CarcinomaMetastatic Esophageal CarcinomaLocally Advanced Biliary Tract CarcinomaLocally Advanced Colorectal CarcinomaLocally Advanced Esophageal CarcinomaLocally Advanced Gastric CarcinomaMetastatic Colorectal Carcinoma (mCRC)Advanced Lung Carcinoma
Interventions
DRUG

Olanzapine

Given PO

DRUG

Placebo Administration

Given PO

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

97239

RECRUITING

OHSU Knight Cancer Institute, Portland

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

OHSU Knight Cancer Institute

OTHER